{"id":3008,"date":"2026-09-15T14:14:35","date_gmt":"2026-09-15T14:14:35","guid":{"rendered":"https:\/\/bookinghospital.org\/?p=3008"},"modified":"2026-09-15T14:16:58","modified_gmt":"2026-09-15T14:16:58","slug":"liver-transplant-for-liver-cancer","status":"publish","type":"post","link":"https:\/\/bookinghospital.org\/tr\/karaciger-kanseri-icin-karaciger-nakli\/","title":{"rendered":"Karaci\u011fer Kanseri ve Nakli: Milan Kriterleri ve \u00d6tesi"},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"3008\" class=\"elementor elementor-3008\">\n\t\t\t\t<div class=\"elementor-element elementor-element-d16e186 e-con-full e-flex e-con e-parent\" data-id=\"d16e186\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-043d061 elementor-widget elementor-widget-html\" data-id=\"043d061\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"html.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div id=\"bh\">\n\n<section class=\"hero\">\n  <div class=\"in\">\n    <p class=\"eyebrow\">Karaci\u011fer nakli \u00b7 Karaci\u011fer kanseri<\/p>\n    <h1>Karaci\u011fer kanseriniz nakil i\u00e7in \u00e7ok mu ilerlemi\u015f durumda?<\/h1>\n    <p class=\"lead\">Karaci\u011fer kanseri olan baz\u0131 hastalar i\u00e7in nakil, hastal\u0131\u011f\u0131 iyile\u015ftirme olas\u0131l\u0131\u011f\u0131 en y\u00fcksek olan tedavidir. Kimin uygun oldu\u011funa dair kurallar di\u011fer hastalarinkinden daha kat\u0131d\u0131r \u2014 ancak bunlar kesin bir evet veya hay\u0131r \u00e7izgisi de\u011fildir. Kriterlerin ve ara\u015ft\u0131rmalar\u0131n ger\u00e7ekte ne s\u00f6yledi\u011fi a\u015fa\u011f\u0131dad\u0131r.<\/p>\n    <p class=\"meta\">Uluslararas\u0131 k\u0131lavuzlara, uzla\u015f\u0131 raporlar\u0131na ve klinik \u00e7al\u0131\u015fmalara dayanarak<\/p>\n  <\/div>\n<\/section>\n\n<section class=\"wrap\">\n\n  <div class=\"ozet\">\n    <h2>K\u0131sa cevap<\/h2>\n    <ul>\n      <li>Bir nakil, hepatosell\u00fcler karsinomu (HCC) olan baz\u0131 hastalar\u0131 iyile\u015ftirebilir, \u00e7\u00fcnk\u00fc bu i\u015flem <b>t\u00fcm\u00f6r ve hastal\u0131kl\u0131 karaci\u011fer birlikte<\/b>.<\/li>\n      <li>The <b>Milano kriterleri<\/b> standart kriter: 5 cm'ye kadar bir t\u00fcm\u00f6r veya her biri en fazla 3 cm olan en fazla \u00fc\u00e7 t\u00fcm\u00f6r.<\/li>\n      <li><b>Milano'nun \u00f6tesi otomatik olarak hay\u0131r demek de\u011fildir.<\/b> Geni\u015fletilmi\u015f kriterler mevcuttur ve t\u00fcm\u00f6rler bazen \u015fu \u015fekilde bilinen s\u0131n\u0131rlar dahilinde k\u00fc\u00e7\u00fclt\u00fclebilir: <b>evre d\u00fc\u015f\u00fcrme<\/b>.<\/li>\n      <li>T\u00fcm\u00f6r boyutu her \u015fey demek de\u011fildir. Kan belirteci <b>AFP<\/b> kanserin neredeyse ayn\u0131 g\u00fc\u00e7te geri gelip gelmeyece\u011fini \u00f6ng\u00f6r\u00fcr.<\/li>\n      <li>Organ naklini genellikle ne engeller: <b>ana kan damarlar\u0131na veya karaci\u011ferin d\u0131\u015f\u0131na yay\u0131ld\u0131<\/b>.<\/li>\n    <\/ul>\n  <\/div>\n\n  <h2>Neden nakil ve kurallar neden kat\u0131<\/h2>\n\n  <p>Karaci\u011fer kanserinin \u00e7o\u011fu, siroz nedeniyle zaten hasar g\u00f6rm\u00fc\u015f bir karaci\u011ferde geli\u015fir. Yaln\u0131zca t\u00fcm\u00f6r\u00fcn \u00e7\u0131kar\u0131lmas\u0131, yeni t\u00fcm\u00f6rlerin olu\u015fabilece\u011fi hastal\u0131kl\u0131 karaci\u011feri geride b\u0131rak\u0131r. Nakil ise her ikisini de ortadan kald\u0131r\u0131r.<\/p>\n\n  <p>Buradaki zorluk, kanser h\u00fccrelerinin ameliyattan \u00f6nce karaci\u011ferden \u00e7oktan yay\u0131lm\u0131\u015f\n     olabilmesidir. Nakilden sonra, organ reddini \u00f6nleyen ila\u00e7lar ba\u011f\u0131\u015f\u0131kl\u0131k\n     sistemini zay\u0131flat\u0131r \u2014 ve v\u00fccutta kalan kanser daha h\u0131zl\u0131 b\u00fcy\u00fcyebilir. Bu nedenle ekipler,\n     kanseri <b>muhtemelen karaci\u011ferle s\u0131n\u0131rl\u0131 kalmas\u0131 muhtemel<\/b>.<\/p>\n\n  <h2>Milano kriterleri<\/h2>\n\n  <p>1996 y\u0131l\u0131nda Milano'daki bir ekip, \u00f6zenle se\u00e7ilmi\u015f hastalar\u0131n nakil sonras\u0131nda iyi durumda oldu\u011funu g\u00f6sterdi. 48 hastadan olu\u015fan orijinal \u00e7al\u0131\u015fmalar\u0131nda, <b>D\u00f6rt y\u0131l sonra 75%'\u00fc hayattayd\u0131<\/b>. Se\u00e7im kurallar\u0131 uluslararas\u0131 standart haline geldi:<\/p>\n\n  <div class=\"tblwrap\">\n    <table>\n      <thead>\n        <tr><th>Milano kriterleri<\/th><th><\/th><\/tr>\n      <\/thead>\n      <tbody>\n        <tr><td><b>Bir t\u00fcm\u00f6r<\/b><\/td><td>5 cm'e kadar<\/td><\/tr>\n        <tr><td><b>Ya da en fazla \u00fc\u00e7 t\u00fcm\u00f6r<\/b><\/td><td>Her biri en fazla 3 cm<\/td><\/tr>\n        <tr><td><b>Ve<\/b><\/td><td>Kan damar\u0131 istilas\u0131 yok, karaci\u011fer d\u0131\u015f\u0131na yay\u0131l\u0131m yok<\/td><\/tr>\n      <\/tbody>\n    <\/table>\n  <\/div>\n\n  <p>Mevcut Avrupa k\u0131lavuzu h\u00e2l\u00e2 referans standart olarak Milano'yu kullanmaktad\u0131r.<\/p>\n\n  <h2>Milano'nun \u00d6tesinde: geni\u015fletilmi\u015f kriterler<\/h2>\n\n  <p>Milan, olas\u0131l\u0131klar\u0131n s\u0131n\u0131r\u0131n\u0131 belirlemek i\u00e7in de\u011fil, g\u00fcvenli olmak \u00fczere tasarlanm\u0131\u015ft\u0131r. O zamandan beri birka\u00e7 ekip, daha b\u00fcy\u00fck veya daha fazla say\u0131da t\u00fcm\u00f6r\u00fc olan baz\u0131 hastalar\u0131n da iyi sonu\u00e7lar ald\u0131\u011f\u0131n\u0131 g\u00f6stermi\u015ftir:<\/p>\n\n  <div class=\"tblwrap\">\n    <table>\n      <thead>\n        <tr><th>Kriterler<\/th><th>S\u0131n\u0131rlar<\/th><th>Neler katt\u0131\u011f\u0131<\/th><\/tr>\n      <\/thead>\n      <tbody>\n        <tr><td><b>UCSF<\/b> (2001)<\/td><td>6,5 cm'den k\u00fc\u00e7\u00fck bir t\u00fcm\u00f6r veya en b\u00fcy\u00fc\u011f\u00fc 4,5 cm'den k\u00fc\u00e7\u00fck ve toplam\u0131 8 cm'den k\u00fc\u00e7\u00fck en fazla \u00fc\u00e7 t\u00fcm\u00f6r<\/td><td>Daha b\u00fcy\u00fck t\u00fcm\u00f6r boyutu<\/td><\/tr>\n        <tr><td><b>Yediye kadar<\/b> (2009)<\/td><td>En b\u00fcy\u00fck t\u00fcm\u00f6r\u00fcn cm cinsinden boyutu + t\u00fcm\u00f6r say\u0131s\u0131 = 7 veya daha az<\/td><td>Milan kriterlerinin d\u0131\u015f\u0131nda ancak yedi-i\u00e7inde olan, mikroskobik damar invazyonu olmayan hastalar aras\u0131nda: <b>71.2%<\/b> 5 ya\u015f\u0131nda hayatta<\/td><\/tr>\n        <tr><td><b>AFP modeli<\/b> (2012)<\/td><td>T\u00fcm\u00f6r boyutunu, say\u0131s\u0131n\u0131 ve AFP seviyesini bir skorda birle\u015ftirir<\/td><td>Sadece boyutu de\u011fil, t\u00fcm\u00f6r biyolojisi<\/td><\/tr>\n        <tr><td><b>Malatya<\/b> (T\u00fcrkiye, 2020)<\/td><td>En b\u00fcy\u00fck t\u00fcm\u00f6r 6 cm veya daha k\u00fc\u00e7\u00fck, AFP 200 ng\/ml veya daha az, GGT 104 IU\/L veya daha az ve iyi veya orta derecede diferansiye t\u00fcm\u00f6r<\/td><td>Kan belirte\u00e7leri ve t\u00fcm\u00f6r derecesi<\/td><\/tr>\n      <\/tbody>\n    <\/table>\n  <\/div>\n\n  <p>Farkl\u0131 merkezler farkl\u0131 geni\u015fletilmi\u015f kriterler kullan\u0131r. Bir merkezde kullan\u0131lan kriterlerin d\u0131\u015f\u0131nda olmak, her zaman bir ba\u015fka merkezde kullan\u0131lan kriterlerin d\u0131\u015f\u0131nda olmak anlam\u0131na gelmez.<\/p>\n\n  <h2>AFP: Kan testi neden tarama kadar \u00f6nemlidir?<\/h2>\n\n  <p>Alfa-fetoprotein (<b>AFP<\/b>) bir\u00e7ok karaci\u011fer kanserinin kan dola\u015f\u0131m\u0131na salg\u0131lad\u0131\u011f\u0131 bir proteindir. Y\u00fcksek bir AFP seviyesi genellikle daha agresif bir t\u00fcm\u00f6re i\u015faret eder.<\/p>\n\n  <p>AFP modelini geli\u015ftiren \u00e7al\u0131\u015fmada, bir puana sahip hastalar <b>2'nin \u00fczerinde<\/b> sahipti\n     <b>50.6%<\/b> kanser n\u00fcks etme riski be\u015f y\u0131l i\u00e7inde. \u015eu puana sahip hastalar:\n     <b>2 veya daha az<\/b> sahptim <b>8.8%<\/b> risk.<\/p>\n\n  <div class=\"box\">\n    <span class=\"etiket\">Avrupa k\u0131lavuzundaki AFP \u00e7izgisi<\/span>\n    <p>AFP'li hastalar <b>1.000 ng\/ml \u00fczerinde<\/b> nakil i\u00e7in de\u011ferlendirilmemelidir \u2014 tedavi seviyeyi d\u00fc\u015f\u00fcr\u00fcp bu seviyede tutmad\u0131\u011f\u0131 s\u00fcrece.<\/p>\n  <\/div>\n\n  <h2>Evre k\u00fc\u00e7\u00fcltme: \u00d6nce kanseri k\u00fc\u00e7\u00fcltmek<\/h2>\n\n  <p>E\u011fer bir t\u00fcm\u00f6r kriterlerin s\u0131n\u0131rlar\u0131n\u0131 a\u015f\u0131yorsa, kemoembolizasyon veya ablasyon gibi do\u011frudan karaci\u011fere uygulanan tedaviler bazen t\u00fcm\u00f6r\u00fc tekrar s\u0131n\u0131rlar i\u00e7ine k\u00fc\u00e7\u00fcltebilir. Buna \u015fu ad\u0131 verilir:\n     <b>evre d\u00fc\u015f\u00fcrme<\/b>.<\/p>\n\n  <ul>\n    <li>Avrupa Organ Nakli Derne\u011fi, <b>transplant kriterlerinin \u00f6tesinde olan, karaci\u011fer d\u0131\u015f\u0131na yay\u0131l\u0131m\u0131 veya b\u00fcy\u00fck kan damarlar\u0131n\u0131n invazyonu bulunmayan t\u00fcm hastalar evre d\u00fc\u015f\u00fcrme (downstaging) a\u00e7\u0131s\u0131ndan de\u011ferlendirilmelidir<\/b>.<\/li>\n    <li>Ba\u015far\u0131, birle\u015ftiren belirlenmi\u015f kriterler kullan\u0131larak de\u011ferlendirilir <b>t\u00fcm\u00f6r boyutu ve AFP<\/b>.<\/li>\n    <li>Yan\u0131t zorunludur <b>zamanla t\u00fckenmek<\/b> nakilden \u00f6nce \u2014 k\u0131sa s\u00fcreli\u011fine k\u00fc\u00e7\u00fcl\u00fcp yeniden b\u00fcy\u00fcyen bir t\u00fcm\u00f6r uyar\u0131 i\u015farettir.<\/li>\n  <\/ul>\n\n  <div class=\"soru\">\n    <h3>Evre d\u00fc\u015f\u00fcrme ger\u00e7ekten i\u015fe yar\u0131yor mu?<\/h3>\n\n    <p>XXL \u00e7al\u0131\u015fmas\u0131 bunu test eden tek randomize \u00e7al\u0131\u015fmad\u0131r. Kanseri Milano kriterlerinin \u00f6tesinde olan ancak ba\u015far\u0131l\u0131 ve kal\u0131c\u0131 bir \u015fekilde evresi k\u00fc\u00e7\u00fclt\u00fclen hastalar, bir nakle veya nakil d\u0131\u015f\u0131 tedavinin s\u00fcrd\u00fcr\u00fclmesine atanm\u0131\u015ft\u0131r.<\/p>\n\n    <div class=\"tblwrap\">\n      <table>\n        <thead>\n          <tr><th>5 ya\u015f\u0131nda iken<\/th><th>Nakil<\/th><th>Nakil yok<\/th><\/tr>\n        <\/thead>\n        <tbody>\n          <tr><td>Ya\u015f\u0131yor<\/td><td><b>77.5%<\/b><\/td><td>31.2%<\/td><\/tr>\n          <tr><td>Ya\u015f\u0131yor ve t\u00fcm\u00f6rs\u00fcz<\/td><td><b>76.8%<\/b><\/td><td>18.3%<\/td><\/tr>\n        <\/tbody>\n      <\/table>\n    <\/div>\n\n    <p>Deneme k\u00fc\u00e7\u00fckd\u00fc \u2014 45 hasta \u2014 ve erken sonland\u0131r\u0131ld\u0131, bu y\u00fczden sonu\u00e7lar dikkatle okunmal\u0131d\u0131r. Ancak fark b\u00fcy\u00fck.<\/p>\n  <\/div>\n\n  <p>Nakil beklerken hastalar ayr\u0131ca alabilir <b>k\u00f6pr\u00fcleme tedavisi<\/b> \u2014 kanseri kontrol alt\u0131nda tutmak i\u00e7in kullan\u0131lan ayn\u0131 karaci\u011fer odakl\u0131 tedaviler. Avrupa uzla\u015f\u0131s\u0131, m\u00fcmk\u00fcn olan her yerde bunu de\u011ferlendirmeyi \u00f6nermektedir. \u0130mm\u00fcnoterapi alm\u0131\u015f hastalar\u0131n bir <b>en az d\u00f6rt haftal\u0131k ar\u0131nma d\u00f6nemi<\/b> transplantasyondan \u00f6nce.<\/p>\n\n  <h2>Canl\u0131 verici sorusu<\/h2>\n\n  <p>Canl\u0131 verici ile nakil, <b>planlanm\u0131\u015f<\/b> \u2014 kanser b\u00fcy\u00fcmeye devam ederken hasta bir bekleme listesinde beklemek zorunda kalmaz. Uluslararas\u0131 canl\u0131 verici k\u0131lavuzu, Milan kriterlerinin \u00f6tesinde kanseri olan hastalar\u0131n <b>fayda sa\u011flayabilir<\/b> canl\u0131 vericili nakilden, ancak <b>s\u0131n\u0131rlar\u0131n ne kadar geni\u015fletilebilece\u011fi konusunda bir anla\u015fma yok<\/b>.<\/p>\n\n  <p>Bu karar\u0131n ikinci bir y\u00f6n\u00fc vard\u0131r. Canl\u0131 bir verici ger\u00e7ek bir risk kabul eder<a href=\"\/living-liver-donor-real-risks-recovery-and-your-rights\/\">yakla\u015f\u0131k 500'de 1<\/a>). Ekip, bu riski al\u0131c\u0131n\u0131n kansersiz kalma y\u00f6n\u00fcndeki ger\u00e7ek\u00e7i \u015fans\u0131yla tartmak zorundad\u0131r. Kanser n\u00fcks etme \u015fans\u0131 \u00e7ok y\u00fcksek oldu\u011funda, d\u00fcr\u00fcst bir ekip bir aile \u00fcyesinden bu riski almas\u0131n\u0131 istemekten ka\u00e7\u0131nmay\u0131 tavsiye edebilir.<\/p>\n\n  <h2>Bir nakil i\u015flemini genellikle ne engeller?<\/h2>\n\n  <ul>\n    <li><b>Kanserin karaci\u011fer d\u0131\u015f\u0131na yay\u0131lmas\u0131.<\/b><\/li>\n    <li><b>B\u00fcy\u00fck kan damarlar\u0131n\u0131n invazyonu<\/b> t\u00fcm\u00f6r taraf\u0131ndan.<\/li>\n    <li><b>1.000 ng\/ml \u00fczeri AFP<\/b> bu, tedaviyle d\u00fc\u015fm\u00fcyor.<\/li>\n    <li>Tedaviye ra\u011fmen b\u00fcy\u00fcmeye devam eden bir kanser.<\/li>\n  <\/ul>\n\n  <div class=\"box efsane\">\n    <span class=\"etiket\">Efsane<\/span>\n    <p><b>\"Milano'nun \u00f6tesi nakil yok demektir.\"<\/b><\/p>\n    <p>Pek \u00e7ok hasta i\u00e7in evet. Ancak geni\u015fletilmi\u015f kriterler, evre d\u00fc\u015f\u00fcrme ve canl\u0131 verici, Milan kriterlerinin \u00f6tesindeki baz\u0131 hastalar\u0131n h\u00e2l\u00e2 de\u011ferlendirilebilece\u011fi anlam\u0131na gelir. Vakan\u0131z\u0131n birden fazla kriter setine g\u00f6re de\u011ferlendirilip de\u011ferlendirilmedi\u011fini sorun.<\/p>\n  <\/div>\n\n  <p>Bir nakil aday\u0131n\u0131n kar\u015f\u0131lamas\u0131 gereken genel ko\u015fullar i\u00e7in bkz.\n     <a href=\"\/liver-transplant-who-can-have-one\/\">Kimler karaci\u011fer nakli olabilir?<\/a>.<\/p>\n\n  <div class=\"yazar\">\n    <div class=\"rozet\">MT<\/div>\n    <div>\n      <h3>T\u0131bbi olarak Prof. Dr. Murat Tuncer taraf\u0131ndan incelenmi\u015ftir.<\/h3>\n      <p>Nefrolog ve nakil hekimi. Bu rehber, BookingHospital t\u0131bbi ekibi taraf\u0131ndan uluslararas\u0131 k\u0131lavuzlar, uzla\u015f\u0131 raporlar\u0131 ve klinik \u00e7al\u0131\u015fmalar temel al\u0131narak haz\u0131rlanm\u0131\u015ft\u0131r.<\/p>\n    <\/div>\n  <\/div>\n\n  <div class=\"cta\">\n    <h2>Kanserinizin s\u0131n\u0131rlar\u0131n arkas\u0131nda oldu\u011fu mu s\u00f6ylendi? Taramalar\u0131n\u0131z\u0131 bize g\u00f6nderin<\/h2>\n    <p>En son BT veya MR raporunuzu, zamana ba\u011fl\u0131 AFP sonu\u00e7lar\u0131n\u0131z\u0131 ve ald\u0131\u011f\u0131n\u0131z herhangi bir tedavinin detaylar\u0131n\u0131 g\u00f6nderin. Cevap hay\u0131r oldu\u011funda bile, bir de\u011ferlendirmenin buna de\u011fip de\u011fmeyece\u011fini size d\u00fcr\u00fcst\u00e7e s\u00f6yleyece\u011fiz.<\/p>\n    <div class=\"btns\">\n      <a class=\"btn btn-1\" href=\"\/medical-tourism\/\">T\u0131bbi raporlar\u0131n\u0131z\u0131 g\u00f6nderin<\/a>\n    <\/div>\n  <\/div>\n\n  <div class=\"uyari\">\n    <p><b>T\u0131bbi sorumluluk reddi.<\/b> Bu makale, yay\u0131nlanm\u0131\u015f k\u0131lavuzlara ve \u00e7al\u0131\u015fmalara dayanan genel bilgiler i\u00e7ermektedir. Ki\u015fisel t\u0131bbi tavsiye niteli\u011finde de\u011fildir, doktor-hasta ili\u015fkisi kurmaz ve multidisipliner bir karaci\u011fer kanseri ve nakil ekibinin de\u011ferlendirmesinin yerini alamaz. Kriterler merkezler aras\u0131nda farkl\u0131l\u0131k g\u00f6sterir ve her hastaya bireysel olarak uygulan\u0131r.<\/p>\n  <\/div>\n\n  <div class=\"kaynak\">\n    <h3>Kaynak\u00e7a<\/h3>\n    <ol>\n      <li>Mazzaferro V, Regalia E, Doci R, ve ark. Sirozlu hastalarda k\u00fc\u00e7\u00fck hepatosell\u00fcler karsinomlar\u0131n tedavisinde karaci\u011fer nakli. <i>N Engl J Med<\/i>\n        1996;334(11):693\u2013699.<\/li>\n      <li>Yao FY, Ferrell L, Bass NM, ve ark. Hepatosell\u00fcler karsinom i\u00e7in karaci\u011fer nakli: t\u00fcm\u00f6r boyutu s\u0131n\u0131rlar\u0131n\u0131n geni\u015fletilmesi sa\u011fkal\u0131m\u0131 olumsuz etkilemez.\n        <i>Hepatoloji<\/i> 2001;33(6):1394\u20131403.<\/li>\n      <li>Mazzaferro V, Llovet JM, Miceli R ve ark. Milan kriterlerinin \u00f6tesindeki hepatoell\u00fcler karsinomlu hastalarda karaci\u011fer nakli sonras\u0131 sa\u011fkal\u0131m\u0131 \u00f6ngorma: retrospektif, ke\u015fifsel bir analiz. <i>Lancet Oncol<\/i> 2009;10(1):35\u201343.<\/li>\n      <li>Duvoux C, Roudot-Thoraval F, Decaens T, ve ark. Hepatosell\u00fcler karsinom i\u00e7in karaci\u011fer transplantation\u0131: alfa-fetoproteini i\u00e7eren bir model Milan kriterlerinin performans\u0131n\u0131 art\u0131r\u0131r.\n        <i>Gastroenteroloji<\/i> 2012;143(4):986\u2013994.<\/li>\n      <li>Ince V, Carr BI, Bag HG, ve ark. Malatya'da b\u00fcy\u00fck hepatosel\u00fcler karsinom i\u00e7in karaci\u011fer nakli: gama glutamil transferaz ve alfa-fetoproteinin rol\u00fc, retrospektif bir kohort \u00e7al\u0131\u015fmas\u0131. <i>World J Gastrointest Surg<\/i> 2020;12(12):520\u2013533.<\/li>\n      <li>Mazzaferro V, Citterio D, Bhoori S, et al. Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b\/3 trial.\n        <i>Lancet Oncol<\/i> 2020;21(7):947\u2013956.<\/li>\n      <li>Claasen MPAW, Sneiders D, Rakk\u00e9 YS ve ark. Hepatosell\u00fcler karsinom i\u00e7in karaci\u011fer naklinde downstaging (evre d\u00fc\u015f\u00fcrme), k\u00f6pr\u00fcleme (bridging) ve imm\u00fcnoterapi \u00fczerine Avrupa Organ Nakli Derne\u011fi (ESOT) uzla\u015f\u0131 raporu. <i>Transpl Int<\/i> 2023;36:11648.<\/li>\n      <li>Avrupa Karaci\u011fer Ara\u015ft\u0131rmalar\u0131 Derne\u011fi. Karaci\u011fer Transplantasyonu \u00dczerine EASL Klinik Uygulama K\u0131lavuzlar\u0131. <i>J Hepatol<\/i> 2024;81(6):1040\u20131086.<\/li>\n      <li>Miller CM, Quintini C, Dhawan A, ve di\u011ferleri. Uluslararas\u0131 Karaci\u011fer Nakli Derne\u011fi Canl\u0131 Vericili Karaci\u011fer Nakli Al\u0131c\u0131s\u0131 K\u0131lavuzu. <i>Nakil<\/i>\n        2017;101(5):938\u2013944.<\/li>\n    <\/ol>\n  <\/div>\n\n<\/section>\n\n<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>Liver transplantation \u00b7 Liver cancer Told your liver cancer is too advanced for a transplant? For some patients with liver cancer, a transplant is the treatment most likely to cure it. The rules on who qualifies are stricter than for other patients \u2014 but they are not a single yes-or-no line. Here is what the [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"elementor_header_footer","format":"standard","meta":{"_surecart_dashboard_logo_width":"180px","_surecart_dashboard_show_logo":true,"_surecart_dashboard_navigation_orders":true,"_surecart_dashboard_navigation_invoices":true,"_surecart_dashboard_navigation_subscriptions":true,"_surecart_dashboard_navigation_downloads":true,"_surecart_dashboard_navigation_billing":true,"_surecart_dashboard_navigation_account":true,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"_joinchat":[],"footnotes":""},"categories":[17],"tags":[],"class_list":["post-3008","post","type-post","status-publish","format-standard","hentry","category-liver-transplant-guide"],"_links":{"self":[{"href":"https:\/\/bookinghospital.org\/tr\/wp-json\/wp\/v2\/posts\/3008","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bookinghospital.org\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bookinghospital.org\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bookinghospital.org\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bookinghospital.org\/tr\/wp-json\/wp\/v2\/comments?post=3008"}],"version-history":[{"count":4,"href":"https:\/\/bookinghospital.org\/tr\/wp-json\/wp\/v2\/posts\/3008\/revisions"}],"predecessor-version":[{"id":3013,"href":"https:\/\/bookinghospital.org\/tr\/wp-json\/wp\/v2\/posts\/3008\/revisions\/3013"}],"wp:attachment":[{"href":"https:\/\/bookinghospital.org\/tr\/wp-json\/wp\/v2\/media?parent=3008"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bookinghospital.org\/tr\/wp-json\/wp\/v2\/categories?post=3008"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bookinghospital.org\/tr\/wp-json\/wp\/v2\/tags?post=3008"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}